Effectiveness and Healthcare Cost of Adding Trastuzumab to Standard Chemotherapy for First-Line Treatment of Metastatic Gastric Cancer: A Population-Based Cohort Study

Effectiveness and Healthcare Cost of Adding Trastuzumab to Standard Chemotherapy for First-Line Treatment of Metastatic Gastric Cancer: A Population-Based Cohort Study

A randomized clinical trial showed that trastuzumab, added to traditional chemotherapy, significantly improved overall survival in human epidermal growth factor receptor 2 (HER2)-overexpressing metastatic gastric cancer patients. This population-based study aimed at evaluating both the clinical and...

Full description

Bibliographic Details
Main Authors: Matteo Franchi, Roberta Tritto, Lorena Torroni, Chiara Reno, Carlo La Vecchia, Giovanni Corrao
Format: Article
Language:English
Published: MDPI AG 2020-06-01
Series:Cancers
Subjects:
gastric cancer
trastuzumab
overall survival
real-word evidence
cost-effectiveness
Online Access:https://www.mdpi.com/2072-6694/12/6/1691

Internet

https://www.mdpi.com/2072-6694/12/6/1691

Similar Items